Physician profile
David C Bell
NPI 1548358716
$1,552.98
in general payments reported to CMS, 2019-2025
26 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $57.68 · 2021: $12.69 · 2022: $67.73 · 2023: $476 · 2024: $405 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $292.45 | 2019-2024 | |
| Astellas Pharma US INC | $260.51 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $151.76 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Coopersurgical, INC. | $110.03 | 2019 | |
| Organon LLC | $106.81 | 2023-2025 | Nexplanon |
| Daiichi Sankyo INC. | $74.86 | 2023-2025 | Injectafer |
| Mayne Pharma Commercial LLC | $70.79 | 2023 | |
| Sumitomo Pharma America, INC. | $65.17 | 2023-2024 | Myfembree |
| Exeltis, USA INC. | $52.52 | 2019-2024 | Slynd |
| Pfizer INC. | $49.81 | 2019-2024 | |
| Gynesonics, INC. | $45.85 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Biogen, INC. | $38.45 | 2024-2025 | Zurzuvae |
| Allergan, INC. | $34.36 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $33.92 | 2019-2020 | |
| Hologic Sales and Service, LLC | $17.59 | 2023 | Coolseal Generator |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $17.11 | 2024 | |
| Alexion Pharmaceuticals, INC. | $16.87 | 2024 | Ultomiris |
| Shield Therapeutics INC | $16.50 | 2025 | |
| Duchesnay USA Incorporated | $15.75 | 2019 | |
| Avion Pharmaceuticals | $14.98 | 2020 | |
| Aspira Women'S Health INC | $14.78 | 2024 | Ova1 |
| Coloplast Corp | $14.12 | 2024 | |
| Optumhealth Care Solutions, LLC | $13.54 | 2024 | Vivify Health Care Team Portal 001, Eitan Medical |
| Channel Medsystems, INC. | $13.34 | 2025 | |
| Merck Sharp & Dohme LLC | $11.11 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.